Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, the impact of Sac/Val in patients presenting with heart failure with preserved ejection fraction (HFp...

Full description

Bibliographic Details
Main Authors: Antje Schauer, Volker Adams, Antje Augstein, Anett Jannasch, Runa Draskowski, Virginia Kirchhoff, Keita Goto, Jeniffer Mittag, Roberta Galli, Anita Männel, Peggy Barthel, Axel Linke, Ephraim B. Winzer
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
HFpEF
ZSF-1
Sacubitril/Valsartan
diastolic dysfunction
skeletal muscle dysfunction
Online Access:https://www.mdpi.com/1422-0067/22/7/3570

Internet

https://www.mdpi.com/1422-0067/22/7/3570

Similar Items